Impact of European Medicines Agency Recommendations for Hypersensitivity Reactions on Intravenous Iron Prescription in Haemodialysis Centres of the Lombardy Region

Overview

Journal J Nephrol

Publisher Springer

Specialty Nephrology

Date 2015 Dec 31

PMID 26715394

Citations 2

Authors

Rodolfo F Rivera

Davide Guido

Lucia Del Vecchio

Enzo Corghi

Marco DAmico

Corrado Camerini

Donatella Spotti

Andrea Galassi

Claudio Pozzi

Giovanni Cancarini

Giuseppe Pontoriero

Francesco Locatelli

Affiliations

Soon will be listed here.

Abstract

Background: The European Medicines Agency (EMA) has recommended measures to minimize the risk of hypersensitivity reactions (HSRs) to intravenous iron (IVFe). We analysed the effects of these recommendations on IVFe clinical management among haemodialysis centres (HDCs) in Lombardy, Italy.

Materials And Methods: A questionnaire was sent to all 117 HDCs to collect information on centre characteristics, e.g. HDC type [hospital centre (HC) vs. centre with limited assistance (CAL)], presence/absence of intensive care unit (ICU) and/or emergency trained staff, IVFe therapy regarding molecules, administration modalities, side effects, and percentage variations in iron prescription between 2014 and 2013 (outcome, Δ-IVFe%). A linear regression model was applied to evaluate the focus effect (β) of HDC type on the outcome, controlling for possible confounding effects of the other characteristics.

Results: Response rate was 73.5 %. IVFe therapy was used in 69.1 % (HDC range 11-100) of patients. Following EMA recommendations, prescription was reduced by 12.6 %, with the largest reduction observed in CALs. No severe HSRs were reported. HCs had more frequently an ICU [97.2 vs. 20 %, odds ratio (OR) = 63.6 (95 % confidence interval 15.56; 537.47), p < 0.001], emergency trained staff [97.2 vs. 61.2 %, OR = 10.7 (2.68; 85.33), p < 0.001] and instrumental facilities (91.7 vs. 58 %, OR = 5.8 (2.03; 23.55), p < 0.001] than CALs. Linear regression demonstrated a significant raw effect of HDC type on Δ- IVFe% [β = 19.6 (9.82; 30.63), p < 0.001]. No association was found when HDC type was adjusted for ICU-presence [β = 6.7 (-2.32; 18.30), p = 0.199] or for all-confounding factors [β = 5.6 (-5.50; 17.08), p = 0.337].

Conclusions: This survey shows a disparity in IVFe therapy prescription following EMA recommendations, which is largely influenced by the presence/absence of ICUs in HD centres.

Citing Articles

Ferric Carboxymatose in Non-Hemodialysis CKD Patients: A Longitudinal Cohort Study.

Minutolo R, Berto P, Liberti M, Peruzzu N, Borrelli S, Netti A J Clin Med. 2021; 10(6).

PMID: 33806864 PMC: 8005153. DOI: 10.3390/jcm10061322.

Safety concerns about intravenous iron therapy in patients with chronic kidney disease.

Del Vecchio L, Longhi S, Locatelli F Clin Kidney J. 2016; 9(2):260-7.

PMID: 26985378 PMC: 4792617. DOI: 10.1093/ckj/sfv142.

References

Allegra V, Mengozzi G, Vasile A . Iron deficiency in maintenance hemodialysis patients: assessment of diagnosis criteria and of three different iron treatments. Nephron. 1991; 57(2):175-82. DOI: 10.1159/000186246. View

Auerbach M, Adamson J, Bircher A, Breymann C, Fishbane S, Gafter-Gvili A . On the safety of intravenous iron, evidence trumps conjecture. Haematologica. 2015; 100(5):e214-5. PMC: 4420237. DOI: 10.3324/haematol.2014.121004. View

. Intravenous iron-containing products: EMA procrastination. Prescrire Int. 2014; 23(151):184-5. View

Litton E, Xiao J, Ho K . Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ. 2013; 347:f4822. PMC: 3805480. DOI: 10.1136/bmj.f4822. View

Sunder-Plassmann G, Horl W . Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant. 1995; 10(11):2070-6. View

Irving M, Craig J, Gallagher M, McDonald S, Polkinghorne K, Walker R . Implementing iron management clinical practice guidelines in patients with chronic kidney disease having dialysis. Med J Aust. 2006; 185(6):310-4. DOI: 10.5694/j.1326-5377.2006.tb00584.x. View

Macdougall I, Tucker B, Thompson J, Tomson C, Baker L, Raine A . A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996; 50(5):1694-9. DOI: 10.1038/ki.1996.487. View

Pfeffer M, Burdmann E, Chen C, Cooper M, de Zeeuw D, Eckardt K . A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361(21):2019-32. DOI: 10.1056/NEJMoa0907845. View

Rampton D, Folkersen J, Fishbane S, Hedenus M, Howaldt S, Locatelli F . Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014; 99(11):1671-6. PMC: 4222472. DOI: 10.3324/haematol.2014.111492. View

10.

Albaramki J, Hodson E, Craig J, Webster A . Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev. 2012; 1:CD007857. DOI: 10.1002/14651858.CD007857.pub2. View

11.

Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A . The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc. 2015; 90(1):12-23. DOI: 10.1016/j.mayocp.2014.10.007. View

12.

Sepandj F, Jindal K, West M, Hirsch D . Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol Dial Transplant. 1996; 11(2):319-22. DOI: 10.1093/oxfordjournals.ndt.a027260. View

13.

St Peter W, Obrador G, Roberts T, Collins A . Trends in intravenous iron use among dialysis patients in the United States (1994-2002). Am J Kidney Dis. 2005; 46(4):650-60. DOI: 10.1053/j.ajkd.2005.06.018. View

14.

Macdougall I, Bock A, Carrera F, Eckardt K, Gaillard C, Van Wyck D . The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale. Nephrol Dial Transplant. 2013; 29(4):843-50. PMC: 3967831. DOI: 10.1093/ndt/gft424. View

15.

Wysowski D, Swartz L, Borders-Hemphill B, Goulding M, Dormitzer C . Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol. 2010; 85(9):650-4. DOI: 10.1002/ajh.21794. View

16.

Fishbane S, Frei G, Maesaka J . Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995; 26(1):41-6. DOI: 10.1016/0272-6386(95)90151-5. View

17.

Weaver W, Hill D, Fahrenbruch C, Copass M, Martin J, Cobb L . Use of the automatic external defibrillator in the management of out-of-hospital cardiac arrest. N Engl J Med. 1988; 319(11):661-6. DOI: 10.1056/NEJM198809153191101. View

18.

Heine-Broring R, Winkels R, Botma A, van Duijnhoven F, Jung A, Kleibeuker J . Dietary Supplement Use and Colorectal Adenoma Risk in Individuals with Lynch Syndrome: The GEOLynch Cohort Study. PLoS One. 2013; 8(6):e66819. PMC: 3688951. DOI: 10.1371/journal.pone.0066819. View

19.

Bircher A, Auerbach M . Hypersensitivity from intravenous iron products. Immunol Allergy Clin North Am. 2014; 34(3):707-23, x-xi. DOI: 10.1016/j.iac.2014.04.013. View

20.

Valenzuela T, Roe D, Nichol G, Clark L, Spaite D, Hardman R . Outcomes of rapid defibrillation by security officers after cardiac arrest in casinos. N Engl J Med. 2000; 343(17):1206-9. DOI: 10.1056/NEJM200010263431701. View